Platinum Priority – Review – Kidney Cancer Editorial by Lori Wood on pp. 621–622 of this issue| Volume 74, ISSUE 5, P611-620, November 01, 2018

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis



      Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC).


      To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3–4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC.

      Evidence acquisition

      A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed. We identified reports and reviewed them according to the Consolidated Standards of Reporting Trials and Standards for the Reporting of Diagnostic Accuracy Studies criteria. Of eight full-text articles that were eligible for inclusion, five studies (two of five were updated analyses) were retained in the final synthesis. Study characteristics were abstracted and the number needed to treat (NNT) per trial was estimated.

      Evidence synthesis

      The three randomized controlled phase III trials included the following comparisons: sunitinib versus placebo or sorafenib versus placebo (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma [ASSURE] study, n = 1943), sunitinib versus placebo (S-TRAC, n = 615), and pazopanib versus placebo (Pazopanib As Adjuvant Therapy in Localized/Locally Advanced RCC After Nephrectomy study, n = 1135). The NNT ranged from 10 (S-TRAC) to 137 (ASSURE study). The pooled analysis showed that VEGFR-targeted therapy was not statistically significantly associated with improved DFS (hazard ratio [HRrandom]: 0.92, 95% confidence interval [CI]: 0.82–1.03, p = 0.16) or OS (HRrandom: 0.98, 95% CI: 0.84–1.15, p = 0.84) compared with the control group. The adjuvant therapy group experienced significantly higher odds of grade 3–4 AEs (ORrandom: 5.89, 95% CI: 4.85–7.15, p < 0.001). In exploratory analyses focusing on patients who started on the full-dose regimen, DFS was improved in patients who received adjuvant therapy (HRrandom: 0.83, 95% CI: 0.73–0.95, p = 0.005).


      This pooled analysis of reported randomized trials did not reveal a statistically significant effect between adjuvant VEGFR-targeted therapy and improved DFS or OS in patients with intermediate/high-risk local or regional fully resected RCC. Improvement in DFS may be more likely with the use of full-dose regimens, pending further results. However, adjuvant treatment was associated with high-grade AEs.

      Patient summary

      Vascular endothelial growth factor receptor–targeted therapy after nephrectomy for localized kidney cancer is not associated with consistent improvements in delaying cancer recurrence or prolonging life and comes at the expense of potentially significant side effects.


      To read this article in full you will need to make a payment


      Subscribe to European Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.
        • Soerjomataram I.
        • Ervik M.
        • et al.
        Cancer IAfRo Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. IARC, Lyon, France2014
        • Janzen N.
        • Kim H.
        • Figlin R.
        • Belldegrun A.
        Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
        Urol Clin North Am. 2003; 30: 843-852
        • Choueiri T.K.
        • Motzer R.J.
        Systemic therapy for metastatic renal-cell carcinoma.
        N Engl J Med. 2017; 376: 354-366
        • Haas N.
        • Manola J.
        • Uzzo R.
        • et al.
        Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
        Lancet. 2016; 387: 2008-2016
        • Ravaud A.
        • Motzer R.J.
        • Pandha H.S.
        • et al.
        Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.
        N Engl J Med. 2016; 375: 2246-2254
        • Motzer R.J.
        • Haas N.B.
        • Donskov F.
        • et al.
        Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma.
        J Clin Oncol. 2017; 35: 3916-3923
        • Haas N.B.
        • Manola J.
        • Dutcher J.P.
        • et al.
        Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of ASSURE randomized trial.
        JAMA Oncol. 2017; 3: 1249-1252
        • Motzer R.J.
        • Ravaud A.
        • Patard J.
        • et al.
        Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results.
        Eur Urol. 2017; 73: 62-68
        • Liberati A.
        • Altman D.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
        J Clin Epidemiol. 2009; 62: e1-e34
      1. Higgins J.P.T. Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, 2011
        • Higgins J.
        • Altman D.
        • Cotzsche P.
        • et al.
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.
        • PRISMA Group
        Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement.
        Int J Surg. 2010; 8: 336-341
        • Altman D.
        • Andersen P.
        Calculating the number needed to treat for trials where the outcome is time to an event.
        BMJ. 1999; 319: 1492-1495
        • Tierney J.
        • Stewart L.
        • Ghersi D.
        • Burdett S.
        • Sydes M.
        Practical methods for incorporating summary time-to-event data into meta-analysis.
        Trials. 2007; 8: 2815-2816
        • Borenstein M.
        • Hedges L.
        • Higgins J.
        • Rothstein H.
        A basic introduction to fixed-effect and random-effects models for meta-analysis.
        Res Synth Methods. 2010; 1: 97-111
        • Hedges L.
        • Pigott T.
        The power of statistical tests in meta-analysis.
        Psychol Methods. 2001; 6: 203-217
        • Casuscelli J.
        • Hsieh J.
        Are we ready for adjuvant sunitinib in high-risk renal cell carcinoma?.
        Eur Urol. 2018; 73: 69-70
        • Gyawali B.
        • Goldstein D.
        The US Food and Drug Administration's approval of adjuvant sunitinib for renal cell cancer. A case of regulatory capture?.
        JAMA Oncol. 2018; 4: 623-624
        • Bex A.
        • Albiges L.
        • Ljunberg B.
        • et al.
        Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma.
        Eur Urol. 2017; 71: 719-722
        • Figlin R.A.
        • Leibovich B.C.
        • Stewart G.
        • Negrier S.
        Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?.
        Ann Oncol. 2018; 29: 324-331
        • Bergers G.
        • Benjamin G.
        Angiogenesis: tumorigenesis and the angiogenic switch.
        Nat Rev Cancer. 2003; 3: 401-410
      2. Sternberg CN, Donskov F, Haas NB, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res. In press.

        • Harshman L.C.
        • Xie W.
        • Moreira R.B.
        • et al.
        Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis.
        Cancer. 2018; 124: 925-933
        • Motzer R.J.
        • Escudier B.
        • McDermott D.
        • et al.
        Nivolumab versus everolimus in advanced renal cell carcinoma.
        N Engl J Med. 2015; 373: 1803-1813

      Linked Article